Abstract:
Prostaglandin E (PGE)-type derivatives and analogs having a 6-keto feature are disclosed, including processes for preparing them and the appropriate intermediates, said derivatives having pharmacological activity.

Description:
CROSS REFERENCE TO RELATED APPLICATIONS 
     This application is a divisional application of co-pending application Ser. No. 829,679, filed Sept. 2, 1977, now pending issuance; which is a continuation-in-part of Ser. No. 755,675, filed Dec. 30, 1976, now abandoned. 
    
    
     DESCRIPTION 
     BACKGROUND OF THE INVENTION 
     The present invention relates to novel 2-decarboxy-2-hydroxymethyl-6-keto-PGE 1  compounds which are useful agents for the induction of prostacyclin-like pharmacological effects. Accordingly, these compounds are useful for pharmacological purposes for which prostacyclin and related substances are employed. The essential material constituting disclosure of the preparation and use of these novel compounds is incorporated here by reference from Ser. No. 829,679, filed Sept. 2, 1977. 
     SUMMARY OF THE INVENTION 
     The present invention particularly provides a compound of the formula ##STR1## wherein W 1  is α-OH:β-H, β-H:β-OH, α-H:β-H, methylene, or α-CH 2  OH:β-H; 
     wherein Q is oxo, α-H:β-H, α-R 8  :β-OH, or α-OH:β-R 8 , wherein R 8  is hydrogen or alkyl of one to 4 carbon atoms, inclusive; 
     wherein R 4  is 
     (1) --C(R 5 )(R 6 )--C g  H 2g  --CH 3   
     (2) --C(R 5 )(R 6 )--Z--(Ph) or 
     (3) cis-CH 2  -CH═CH-CH 2  CH 3 , 
     wherein C g  H 2g  is alkylene of one to 9 carbon atoms, inclusive, with one to 5 carbon atoms, inclusive, in the chain between --CR 5  R 6  -- and terminal methyl, wherein R 5  and R 6  are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R 5  and R 6  is fluoro only when the other is hydrogen or fluoro and the further proviso that neither R 5  nor R 6  is fluoro when Z is oxa (--O--); wherein Z represents an oxa atom (--O--) or C jH2j  is a valence bond or alkylene of one to 9 carbon atoms, inclusive, with one to 6 carbon atoms, inclusive between CR 5  R 6  -- and the (Ph); wherein (Ph) is phenyl or phenyl substituted by (T)s, 
     wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR 7 , wherein R 7  is alkyl of one to 4 carbon atoms, inclusive, 
     wherein s is zero, one, 2 or 3, with the proviso that not more than two T&#39;s are other than alkyl and when s is 2 or 3 the T&#39;s are either the same or different; 
     wherein D is 
     (1) --(CH 2 ) d  --C(R 2 ) 2  -- 
     (2) --CH 2  --O--CH 2  --Y-- or 
     (3) --CH 2  --CH═CH-- 
     wherein d is zero to 5, R 2  is hydrogen, methyl, or fluoro, being the same or different with the proviso that one R 2  is not methyl when the other is fluoro, and Y is a valence bond, --CH 2  -- or --(CH 2 ) 2  --, and 
     wherein X is 
     (1) trans--CH═CH-- 
     (2) cis--CH═CH-- 
     (3) --C.tbd.C-- 
     (4) --CH 2  CH 2  --. 
     With regard to the divalent substituents described above, e.g., Q and W 1 , these divalent radicals are defined as α-R i  :β-R j , where Ri represents a substituent of the divalent moiety of the alpha configuration with respect to the cyclopentane ring and R j  represents a substituent to the divalent moiety of the beta configuration with respect to the cyclopentane ring. Accordingly, when Q is defined as α-OH:β-R 8 , the hydroxy of the Q moiety is in the alpha configuration, i.e. as in prostacyclin, and the R 8  substituent is in the beta configuration. Not all carbon atoms to which such divalent moieties are attached represent asymmetric centers. For example, when both valence bonds are to hydrogen (e.g., W 1  or Q is α-H:β-H), then no asymmetric center is present. 
    
    
     DESCRIPTION OF THE PREFERRED EMBODIMENTS 
     The present invention particularly relates to the following chemical compounds: 
     2-decarboxy-2-hydroxymethyl-6,15-diketo-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-6-keto-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-16,16-dimethyl-6-keto-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-16-phenoxy-17,18,19,20-tetranor-6-keto-PGE.sub.1 ; 
     2-decarboxy-2-hydroxymethyl-16-phenyl-17,18,19,20-tetranor-6-keto-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-17-phenyl-18,19,20-trinor-6-keto-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-15(S)-15-methyl-6-keto-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-(15R)-15-methyl-6-keto-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-6-keto-13,14-didehydro-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-6-keto-13,14-didehydro-(15R)-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-6-keto-13,14-dihydro-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-2,2-difluoro-6-keto-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-2,2-difluoro-16,16-dimethyl-6-keto-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-2,2-difluoro-16-phenoxy-17,18,19,20-tetranor-6-keto-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-2,2-difluoro-(15S)-15-methyl-6-keto-PGE 1  ; 
     2-decarboxy-2-hydroxymethyl-2,2-difluoro-13,14-didehydro-6-keto-PGE 1  ; and 
     2-decarboxy-2-hydroxymethyl-2,2-difluor-13,14-dihydro-6-keto-PGE 1 .